SCHEMBL1685452

SCHEMBL1685452

NCCCN(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.88

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.53
PRMT6 Q96LA8 1/20 0.53
PRMT8 Q9NR22 1/20 0.53
HDAC3 O15379 2/20 0.50
HDAC1 Q13547 2/20 0.50
HDAC2 Q92769 2/20 0.50
HDAC8 Q9BY41 2/20 0.50
NCOR2 Q9Y618 2/20 0.50
MAOA P21397 1/20 0.50
GBA1 P04062 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL713789 0.96 CARM1 (0.53) CARM1PRMT6PRMT8HDAC3HDAC1
SCHEMBL25221689 0.94 CARM1 (0.52) CARM1PRMT6PRMT8HDAC3HDAC1
SCHEMBL5741392 0.94 MAOA (0.54) CARM1PRMT6PRMT8HDAC3HDAC1
SCHEMBL8993155 0.92 HDAC3 (0.54) CARM1PRMT6PRMT8HDAC3HDAC1
SCHEMBL17527074 0.92 MAOA (0.52) CARM1PRMT6PRMT8HDAC3HDAC1
SCHEMBL1983580 0.92 HDAC3 (0.54) CARM1PRMT6PRMT8HDAC3HDAC1
SCHEMBL8708196 0.92 HDAC3 (0.54) CARM1PRMT6PRMT8HDAC3HDAC1
SCHEMBL713894 0.92 CARM1 (0.50) CARM1PRMT6PRMT8HDAC3HDAC1
SCHEMBL20989945 0.92 CARM1 (0.55) CARM1PRMT6PRMT8HDAC3HDAC1
SCHEMBL8027241 0.92 HDAC3 (0.50) CARM1PRMT6PRMT8HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115066238-A Preparation of cannabichromenes and related cannabinoids 海湾医学公司 2022-09-16 CN claimed
EP-4306566-B1 CURABLE RESIN COMPOSITION, CURED PRODUCT AND ADHESIVE ADEKA CORP (JP) 2026-05-06 EP disclosed
US-12590178-B2 Curable resin composition and method for suppressing curing shrinkage of curable resin composition ADEKA CORPORATION (JP) 2026-03-31 US disclosed
EP-4306567-B1 CURABLE RESIN COMPOSITION, CURED PRODUCT, AND ADHESIVE ADEKA CORP (JP) 2025-06-04 EP disclosed
US-12269917-B2 Curable resin composition ADEKA CORPORATION (JP) 2025-04-08 US disclosed
US-20250109240-A1 ONE-PACK TYPE EPOXY RESIN COMPOSITION ADEKA CORPORATION (JP) 2025-04-03 US disclosed
WO-2025062839-A1 COMPOUND, EPOXY RESIN, CURABLE COMPOSITION, MATERIAL FOR RECYCLING, CURED ARTICLE, METHOD FOR PRODUCING CURED ARTICLE, METHOD FOR PRODUCING DECOMPOSITION PRODUCT, AND DECOMPOSITION METHOD 株式会社ADEKA 2025-03-27 WO disclosed
WO-2025047655-A1 BLOCK URETHANE MATERIAL, COMPOSITION, CURED PRODUCT, METHOD FOR PRODUCING CURED PRODUCT, AND BLOCK URETHANE COMPOUND CONTAINED THEREIN 株式会社ADEKA 2025-03-06 WO disclosed
EP-4491653-A1 ONE-PACK TYPE EPOXY RESIN COMPOSITION ADEKA CORPORATION (JP) 2025-01-15 EP disclosed
US-20250002707-A1 CURABLE RESIN COMPOSITION, CURED PRODUCT, AND ADHESIVE ADEKA CORPORATION (JP) 2025-01-02 US disclosed
US-6057337-A USEFUL FOR CARE, IMPROVEMENT OR PREVENTION OF HAIR LOSS SHISEIDO CO., LTD. (JP) 2000-05-02 US disclosed
EP-0989123-A1 Benzimidazole derivative, hair growth promoter and external composition for skin using the same SHISEIDO COMPANY LIMITED (JP) 2000-03-29 EP disclosed
EP-0940390-A1 6- (Substituted-methyl) -3- cyclohexenyl formamide derivative, hair growth promoter and external composition for skin SHISEIDO COMPANY LIMITED (JP) 1999-09-08 EP disclosed
EP-0933361-A1 1,2-Di-substituted piperidine derivatives as hair growth promoter SHISEIDO COMPANY LIMITED (JP) 1999-08-04 EP disclosed
CN-1224712-A 1,2-Di-substituted benzene-carboxamide derivative, hair growth promoter and external composition for skin using the same SHISEIDO CO LTD (JP) 1999-08-04 CN disclosed
EP-0911320-A2 1,2-Di-substituted benzenecarboxamide derivative, hair growth promoter and external composition for skin using the same SHISEIDO COMPANY LIMITED (JP) 1999-04-28 EP disclosed
EP-0199963-B1 ETHOSUXIMIDE ASSAY TRACERS, IMMUNOGENS AND ANTIBODIES ABBOTT LABORATORIES (US) 1991-10-23 EP disclosed
EP-0199963-A1 Ethosuximide assay tracers, immunogens and antibodies ABBOTT LABORATORIES (US) 1986-11-05 EP disclosed
US-4267102-A Bleomycin group antibiotics NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1981-05-12 US disclosed
US-RE30451-E ANTITUMOR AGENTS Zaidan Jojin Biseibutsu Kagaku Kenkyu Kai (JP) 1980-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12590178-B2 Curable resin composition and method for suppressing curing shrinkage of curable resin composition SEM1, RER1, JMJD6 CARM1 4/4885PRMT6 178/4885PRMT8 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.